Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $324.1111.
A number of brokerages have recently commented on KRYS. Jefferies Financial Group lifted their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating for the company. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Guggenheim lifted their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th.
View Our Latest Stock Analysis on KRYS
Krystal Biotech Stock Up 2.6%
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, sell-side analysts anticipate that Krystal Biotech will post 7.83 EPS for the current fiscal year.
Insider Activity
In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the transaction, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.
Institutional Investors Weigh In On Krystal Biotech
Several large investors have recently modified their holdings of the stock. Avoro Capital Advisors LLC grew its position in Krystal Biotech by 4.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after buying an additional 111,111 shares during the last quarter. State Street Corp raised its position in Krystal Biotech by 10.5% during the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after buying an additional 128,639 shares during the last quarter. Soleus Capital Management L.P. lifted its stake in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Krystal Biotech by 5.5% in the third quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock valued at $94,261,000 after acquiring an additional 28,075 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Krystal Biotech by 13.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 529,955 shares of the company’s stock worth $130,656,000 after acquiring an additional 62,897 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Articles
- Five stocks we like better than Krystal Biotech
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
